## **Andreas Conca**

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9499230/publications.pdf

Version: 2024-02-01

257101 197535 2,477 64 24 49 h-index citations g-index papers 75 75 75 3016 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Venlafaxine and O-desmethylvenlafaxine serum levels are positively associated with antidepressant response in elder depressed out-patients. World Journal of Biological Psychiatry, 2022, 23, 183-190.	1.3	5
2	Antidepressant efficacy is correlated with plasma levels: mega-analysis and further evidence. International Clinical Psychopharmacology, 2022, 37, 29-37.	0.9	7
3	Extremely High-Dosage Zolpidem Poisoning With Favorable Outcome. Journal of Clinical Psychopharmacology, 2021, 41, 222-223.	0.7	2
4	Switch to 3-Month Long-Acting Injectable Paliperidone May Decrease Plasma Levels. Journal of Clinical Psychopharmacology, 2021, 41, 694-696.	0.7	3
5	Methylphenidate challenge test in adults with attention deficit/hyperactivity disorder (ADHD): Clinical effects and their predictors. Human Psychopharmacology, 2020, 35, e2740.	0.7	O
6	Serum Aripiprazole Concentrations Prehemodialysis and Posthemodialysis in a Schizophrenic Patient With Chronic Renal Failure. Journal of Clinical Psychopharmacology, 2020, 40, 200-202.	0.7	6
7	Predictors of stigma in a sample of mental health professionals: Network and moderator analysis on gender, years of experience, personality traits, and levels of burnout. European Psychiatry, 2020, 63, e4.	0.1	22
8	Plasma Risperidone-related Measures in Children and Adolescents with Oppositional Defiant/Conduct Disorders. Clinical Psychopharmacology and Neuroscience, 2020, 18, 41-48.	0.9	4
9	Duloxetine plasma level and antidepressant response. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2019, 92, 127-132.	2.5	23
10	TDM in psychiatry and neurology: A comprehensive summary of the consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology, update 2017; a tool for clinicians. World Journal of Biological Psychiatry, 2018, 19, 162-174.	1.3	103
11	Exploring the relationships among personality traits, burnout dimensions and stigma in a sample of mental health professionals. Psychiatry Research, 2018, 264, 327-333.	1.7	33
12	Factors associated with suicide: Case-control study in South Tyrol. Comprehensive Psychiatry, 2018, 80, 150-154.	1.5	15
13	Seizure Adequacy Markers and the Prediction of Electroconvulsive Therapy Response. Journal of ECT, 2016, 32, 88-92.	0.3	47
14	Risky use and misuse of alcohol and cigarettes in psychiatric inpatients: a screening questionnaire study. Comprehensive Psychiatry, 2016, 70, 9-16.	1.5	5
15	Differences among South Tyrolean suicides: a psychological autopsy study. Wiener Klinische Wochenschrift, 2016, 128, 125-130.	1.0	6
16	Sexual Dysfunction Related to Drugs: a Critical Review. Part V: $\hat{l}_{\pm}$ -Blocker and 5-ARI Drugs. Pharmacopsychiatry, 2016, 49, 3-13.	1.7	33
17	On the significance of elektroconvulsive therapy in the treatment of severe mental diseases. Wiener Klinische Wochenschrift, 2015, 127, 297-302.	1.0	17
18	MTHFR: Genetic variants, expression analysis and COMT interaction in major depressive disorder. Journal of Affective Disorders, 2015, 183, 179-186.	2.0	17

#	Article	IF	CITATIONS
19	Sexual Dysfunction Related to Drugs: A Critical Review. Part IV: Cardiovascular Drugs. Pharmacopsychiatry, 2015, 48, 1-6.	1.7	44
20	Bio-psycho-social Aspects of an Overall Treatment Plan. Deutsches A& #x0308; rzteblatt International, 2015, 112, 419.	0.6	1
21	Sexual Dysfunction Related to Psychotropic Drugs: A Critical Review. Part III: Mood Stabilizers and Anxiolytic Drugs. Pharmacopsychiatry, 2014, 47, 1-6.	1.7	47
22	Association between baseline serum vascular endothelial growth factor levels and response to electroconvulsive therapy. Acta Psychiatrica Scandinavica, 2014, 129, 461-466.	2.2	34
23	The association between suicide and the utilization of mental health services in South Tirol, Italy: A psychological autopsy study. International Journal of Social Psychiatry, 2014, 60, 30-39.	1.6	11
24	Dried blood spot testing: a novel approach for the therapeutic drug monitoring of ziprasidone-treated patients. Bioanalysis, 2014, 6, 1487-1495.	0.6	20
25	A fast and feasible microextraction by packed sorbent (MEPS) procedure for HPLC analysis of the atypical antipsychotic ziprasidone in human plasma. Journal of Pharmaceutical and Biomedical Analysis, 2014, 88, 467-471.	1.4	28
26	Differential impairment of interhemispheric transmission in bipolar disease. Experimental Brain Research, 2013, 230, 175-185.	0.7	4
27	Sexual Dysfunction Related to Psychotropic Drugs: A Critical Review Part II: Antipsychotics. Pharmacopsychiatry, 2013, 46, 201-208.	1.7	79
28	Sexual Dysfunction Related to Psychotropic Drugs: A Critical Review - Part I: Antidepressants. Pharmacopsychiatry, 2013, 46, 191-199.	1.7	68
29	Sicherheits- und Nebenwirkungsprofil der EKT. , 2013, , 81-95.		2
30	Rechtsmedizinische Aspekte der EKT in Italien. , 2013, , 229-234.		0
31	EKT: Komedikation und begleitende Therapien. , 2013, , 155-171.		0
32	ErbB3 mRNA leukocyte levels as a biomarker for major depressive disorder. BMC Psychiatry, 2012, 12, 145.	1.1	16
33	Italian psychiatric reform 1978: milestones for Italy and Europe in 2010?. European Archives of Psychiatry and Clinical Neuroscience, 2011, 261, 135-139.	1.8	10
34	AGNP Consensus Guidelines for Therapeutic Drug Monitoring in Psychiatry: Update 2011. Pharmacopsychiatry, 2011, 44, 195-235.	1.7	774
35	Therapeutic Drug Monitoring in Psychiatry. Pharmacopsychiatry, 2011, 44, 193-194.	1.7	0
36	Therapeutic Drug Monitoring in Italian Psychiatry. Pharmacopsychiatry, 2011, 44, 259-262.	1.7	24

#	Article	IF	CITATIONS
37	Incidence of seclusion and restraint in psychiatric hospitals: a literature review and survey of international trends. Social Psychiatry and Psychiatric Epidemiology, 2010, 45, 889-897.	1.6	300
38	Aspetti neurofisiologici e neuropsichiatrici della stimolazione magnetica transcranica. Quaderni Italiani Di Psichiatria, 2010, 29, 122-133.	0.1	1
39	Socioeconomic Risk Factors and Depressive Symptoms in Alcohol Use Disorders Among Male Suicides in South Tirol, Italy. Journal of Addictive Diseases, 2010, 29, 466-474.	0.8	4
40	Impact of seizure duration in maintenance electroconvulsive therapy. Psychiatry and Clinical Neurosciences, 2009, 63, 769-771.	1.0	5
41	Frequency of and rationales for the combined use of electroconvulsive therapy and antiepileptic drugs in Austria and the literature. World Journal of Biological Psychiatry, 2009, 10, 836-845.	1.3	20
42	Repetitive transcranial magnetic stimulation in a patient with atypical Todd's postepileptic paralysis. Psychiatry and Clinical Neurosciences, 2008, 62, 368-368.	1.0	3
43	Repetitive Transcranial Magnetic Stimulation in Bulimia Nervosa: Preliminary Results of a Single-Centre, Randomised, Double-Blind, Sham-Controlled Trial in Female Outpatients. Psychotherapy and Psychosomatics, 2008, 77, 57-60.	4.0	54
44	Repetitive Transcranial Magnetic Stimulation in Augmentation of Antidepressant Drugs., 2007,, 84-96.		1
45	Clinical efficacy and cognitive side effects of bifrontal versus right unilateral electroconvulsive therapy (ECT): A short-term randomised controlled trial in pharmaco-resistant major depression. Journal of Affective Disorders, 2007, 101, 149-157.	2.0	53
46	Post-traumatic stress disorder and amygdala-hippocampectomy. Acta Psychiatrica Scandinavica, 2006, 113, 360-363.	2.2	31
47	A case of delayed galactorrhoea as an adverse event of overlapping haloperidol and clozapine administration. International Journal of Neuropsychopharmacology, 2005, 8, 303-305.	1.0	1
48	ECT response after relapse during continuation repetitive transcranial magnetic stimulation. A case report. European Psychiatry, 2004, 19, 118-119.	0.1	3
49	Antidepressant-associated mania with escitalopram. European Psychiatry, 2004, 19, 455-456.	0.1	6
50	No Deterioration of Cognitive Performance in an Aggressive Unilateral and Bilateral Antidepressant rTMS Add-On Trial. Journal of Clinical Psychiatry, 2004, 65, 772-782.	1.1	63
51	Can Bilateral Prefrontal Repetitive Transcranial Magnetic Stimulation (rTMS) Induce Mania?. Journal of Clinical Psychiatry, 2004, 65, 1575-1576.	1.1	30
52	Therapeutic drug monitoring of trazodone: are there pharmacokinetic interactions involving citalopram and fluoxetine?. International Journal of Clinical Pharmacology and Therapeutics, 2004, 42, 120-124.	0.3	16
53	Simultaneous pattern of rCBF and rCMRGlu in continuation ECT: case reports. Psychiatry Research - Neuroimaging, 2003, 124, 191-198.	0.9	11
54	Zuclopenthixol-acetate treatment in catatonic patients: the implication of iron metabolism. European Psychiatry, 2003, 18, 28-31.	0.1	9

#	Article	IF	CITATIONS
55	Etomidate vs. Thiopentone in Electroconvulsive Therapy. Pharmacopsychiatry, 2003, 36, 94-97.	1.7	28
56	Effect of Chronic Repetitive Transcranial Magnetic Stimulation on Regional Cerebral Blood Flow and Regional Cerebral Glucose Uptake in Drug Treatment-Resistant Depressives. Neuropsychobiology, 2002, 45, 27-31.	0.9	40
57	Simultaneous quantification of citalopram, clozapine, fluoxetine, norfluoxetine, maprotiline, desmethylmaprotiline and trazodone in human serum by HPLC analysis. International Journal of Clinical Pharmacology and Therapeutics, 2002, 40, 554-559.	0.3	33
58	Combining high and low frequencies in rTMS antidepressive treatment: preliminary results. Human Psychopharmacology, 2002, 17, 353-356.	0.7	48
59	Low frequency rTMS as an add-on antidepressive strategy: heterogeneous impact on 99mTc-HMPAO and 18F-FDG uptake as measured simultaneously with the double isotope SPECT technique. Pilot study. Nuclear Medicine Communications, 2001, 22, 867-873.	0.5	27
60	Maintenance Electroconvulsive Therapy in Affective and Schizoaffective Disorder. Neuropsychobiology, 2001, 43, 23-28.	0.9	63
61	A Case of Pharmacokinetic Interference in Comedication of Clozapine and Valproic Acid. Pharmacopsychiatry, 2000, 33, 234-235.	1.7	32
62	Preliminary findings of simultaneous 18F-FDG and 99mTc-HMPAO SPECT in patients with depressive disorders at rest: differential correlates with ratings of anxiety. Psychiatry Research - Neuroimaging, 2000, 98, 43-54.	0.9	20
63	Does a Glutamate Receptor Blocker (Caroverine) Enhance Haloperidol in the Treatment of Schizophrenia?. Neuropsychobiology, 1999, 40, 140-141.	0.9	1
64	Combining nefazodone and midazolam during ECT. European Psychiatry, 1999, 14, 360-362.	0.1	3